Zevra Therapeutics Inc (ZVRA) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Zevra Therapeutics Inc   (NASDAQ: ZVRA)


Zevra Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Zevra Therapeutics Inc's ROI in the third quarter of 2026?
Zevra Therapeutics Inc achieved a return on average invested assets (ROI) of 30.96 % in its third quarter of 2026, this is above ZVRA's average return on investment of -124.28%.
Zevra Therapeutics Inc invested over the 12 months ending in its third quarter of 2026 $251 million

ROI has improved compared to 23.75% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 43 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 90 to 92.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 31.8 % 44.61 % 69.12 % 60.8 % 55.04 %
Y / Y Net Income Change TTM 119.83 % 2090.02 % - - -
Investment (TTM) in Millions 272 254 232 245 244
Return On Investment (TTM) 30.96 % 23.75 % 52.39 % 38.59 % 18.56 %
ZVRA's Overall Ranking # 92 # 90 # 75 # 273 #
Seq. Investment Change TTM 2.89 % 2.81 % 9.95 % 13.32 % 12.89 %
Seq. Net Income Change TTM 34.11 % -53.39 % 49.25 % 135.61 % 1236.04 %
Net Income (TTM) in Millions 78 58 124 83 35

ZVRA Company Profile >> Back to ZVRA Roi Comparisons >> See Annual ZVRA Return On Investment



Return On Investment ZVRA's Ranking
Within: No.
Industry # 22
Sector # 44
Overall # 92

Return On Investment Statistics
High Average Low
50.45 %
-124.28 %
-942.61 %
(Mar 31 2026)   (Dec 31 2019)



  News about Zevra Therapeutics Inc Return on Investment ROI

Zevra Therapeutics Announces Organizational Changes

December 6, 2024

Article for the CSI MarketZevra Therapeutics: Transformational Challenges Amidst Financial Strain in Rare Disease TherapeuticsCELEBRATION, Fla. — In a striving industry defined by rapid innovation and harsh competition, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) finds itself at a critical juncture. The company, dedicated to addressing the unmet therapeutic needs of patients afflicted by rare diseases, recently implemented significant organizational changes aimed at redefining its future trajectory. Yet, behind this ambitious transformation lurks a troubling financial backdrop that raises questions about its sustainability.As of the third quarter of 2024, Zevra recorded a staggering cumulative net loss of $85 million, translating to a disconcerting return on investment (ROI) of -69.18%. With these figures, it becomes apparent why the company is shifting gears; it currently ranks below 3,200 other companies within the healthcare sector in terms of ROI, a clear signal of financial instability. This downward trend forced Zevra into a performance re-evaluation, prompting its latest strategic overhaul.





Financial Statements
Zevra Therapeutics Inc's III. Quarter Investments $ 272 Millions ZVRA's Balance sheet
Zevra Therapeutics Inc's III. Quarter Income $ 19 Millions Quarterly ZVRA's Income Statement
ZVRA's Income by Division See ZVRA's Income by Division


ZVRA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 245 144 99 104 129
Y / Y Investment Growth 70.38 % 46.1 % -5.01 % -19.35 % 3404.25 %
Net Income in Millions 83 -106 -46 -42 -9
Y / Y Net Income Growth - - - - -
Annual Return On Investment 33.91 % -73.24 % -46.7 % -40.02 % -6.65 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 33.91 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ZVRA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ZVRA's Competitors
Subscribers only: Roi for Zevra Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for ZVRA's Customers

Other Ratios
ZVRA's Roa ZVRA's Inventory Turnover Ratio ZVRA's Growth Rates ZVRA's Dividend Statistics
ZVRA's Profitability Ratios ZVRA's Asset Turnover Ratio ZVRA's Dividend Growth
ZVRA's Roe ZVRA's Valuation Ratios ZVRA's Financial Strength Ratios ZVRA's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %

Date modified: 2026-11-06T12:58:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.